Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade.
Affiliation
CRUK Manchester Institute and The Christie NHS Foundation Trust, The University of Manchester, Manchester, M20 4GJIssue Date
2018-04-11
Metadata
Show full item recordAbstract
Ipilimumab is a licensed immunotherapy for metastatic melanoma patients and, in the US, as adjuvant treatment for high risk melanoma radically resected. The use of ipilimumab is associated with a typical but unpredictable pattern of side effects. The purpose of this study was to identify clinical features and blood biomarkers capable of predicting ipilimumab related toxicity.Citation
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. 2018, 16(1): 94 J Transl MedJournal
Journal of Translational MedicineDOI
10.1186/s12967-018-1467-xPubMed ID
29642948Type
ArticleLanguage
enISSN
1479-5876ae974a485f413a2113503eed53cd6c53
10.1186/s12967-018-1467-x